Startups
Repligen is a bioprocessing-focused life sciences company bringing over 35 years of expertise and innovation to our customers. We are inspiring advances in bioprocessing through the development and commercialization of high-value products and flexible solutions that address critical steps in the production of biologic drugs, principally monoclonal antibodies.
Our manufacturing facilities are located at our Waltham, Massachusetts headquarters in the USA, and in Lund, Sweden, Weingarten, Germany , Rancho Dominguez, CA and Shrewsbury, MA. We market our products globally through a direct commercial organization in the U.S., Europe and Asia, as well as through strategic partners in select markets.
Our manufacturing facilities are located at our Waltham, Massachusetts headquarters in the USA, and in Lund, Sweden, Weingarten, Germany , Rancho Dominguez, CA and Shrewsbury, MA. We market our products globally through a direct commercial organization in the U.S., Europe and Asia, as well as through strategic partners in select markets.
Overview
Location
United States, Massachusetts, Waltham
Employees
1001-5000
Founded date
1981
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 2, 2025 | Thermo Fisher's Strategic Acquisition: A Game Changer in Bioprocessing | In a bold move, Thermo Fisher Scientific has announced its acquisition of Solventum, a filtration and purification business, for a staggering $4.1 billion. This strategic purchase marks a significant step for Thermo Fisher as it seeks to bo... |
| Feb 27, 2025 | Американский производитель лекарств Thermo Fisher покупает бизнес по очистке и фильтрации Solventum за $4,1 млрд | По словам аналитика Leerink Partners Пунита Суды, сделка должна позволить Thermo войти в категорию фильтрации в сфере биопереработки, где позиции ее конкурентов Danaher и Repligen более сильны. В прошлом месяце компания прогнозировала годов... |
| Mar 17, 2014 | Biogen, Atlas Venture collaborate on treatment for ataxia | Atlas Venture formed Ataxion last year when it licensed the technology from Danish biotech company Aniona, since renamed Saniona. The treatments under development focused on using potassium channel activators to protect Purkinje cells, the ... |
| Mar 26, 2008 | Repligen Launches Trial of Imaging Agent | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Repligen (NASDAQ: RGEN) of Waltham, MA, has begun a Phase 3 clinical trial of an imaging agent that would enhance the ability of magnetic resonance imaging (MRI) to detect abn... |
| Sep 17, 2007 | Good News and Bad News for University Endowments, ImClone and Repligen Reach Settlement, Venture Deals, Mergers, Acquisitions, and More | Share Share on Facebook Share on Twitter LinkedIn Email Reprints Last week left us with lots to talk about, so let’s get right to it. —In venture news, RFID infrastructure firm Tagsys of Cambridge, MA, closed a $16 million second tranche of... |
| Biogen, Atlas Venture collaborate on treatment for ataxia | A biotech startup formed by Atlas Venture is collaborating with Biogen Idec to develop a treatment for inherited forms of Ataxia– a degenerative neurological condition that leads to physical disabilities, according to a company statement. T... |
Reviews 0
FAQ about Repligen Corporation
When was Repligen Corporation founded?
Repligen Corporation was founded in 1981.
What has the press written about Repligen Corporation?
Parsers VC has collected 7 articles mentioning Repligen Corporation, among them “Thermo Fisher's Strategic Acquisition: A Game Changer in Bioprocessing” (Mar 2, 2025) and “Американский производитель лекарств Thermo Fisher покупает бизнес по очистке и фильтрации Solventum за $4,1 млрд” (Feb 27, 2025).
Is Repligen Corporation still active?
Yes, Repligen Corporation is active; its latest activity on Parsers VC dates from Nov 2, 2026.